Skip to main content
An official website of the United States government
Principal Investigator
David T. Marshall
Awardee Organization

Medical University Of South Carolina
United States

Fiscal Year
2025
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Medical University of South Carolina NCORP Minority/Underserved Community Site

The Medical University of South Carolina/Hollings Cancer Center (MUSC/HCC) aims to expand and enhance the NCORP trial portfolio by accruing from other medically overlooked groups into NCORP studies, share expertise and experience on broadening recruitment and retention and leveraging local knowledge within the NCORP community, and contribute to the development and implementation of cancer care and cancer delivery research. During the current project period, the MUSC NCORP-MU, which is comprised of three MUSC/HCC sub-affiliates and community oncology primary affiliates, has made significant contributions to the NCORP program through the effective and efficient accrual of historically overlooked patient populations and leadership that has shaped the scientific agenda for clinical trials, disproportional cancer health outcomes, and cancer care delivery research. These accomplishments were made possible through a highly invested and transdisciplinary investigative team consisting of David T. Marshall, MD (Radiation Oncology). Craig Lockhart, MD, MHS, (Medical Oncology), Marvella E. Ford, PhD (Public Health Sciences), and Evan Graboyes, MD, MPH (Otolaryngology and Public Health Sciences). The multi-PI team works hand-in hand with the clinical research operational leaders at the MUSC/HCC and local clinical investigative team at the NCORP affiliate location to establish and manage a robust clinical research operation to add value to NCORP. This leadership team has also worked collaboratively with other committed clinical and cancer control researchers, oncology care providers, cancer patients, and survivors in our catchment areas to advance all types of cancer research through the NCORP research bases. The MUSC NCORP-MU aims to improve fairness and access to clinical research in medically overlooked groups in order to enhance the quality of cancer care delivery and reduce differences in cancer health outcomes within South Carolina and communities across the US.

Publications

  • Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, Sharer CW, Burton GV, Kuzma CS, Moseley A, Lew DL, Fisch MJ, Moinpour CM, Hershman DL, Wade JL 3rd. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Feb 1;36(4):326-332. Epub 2017 Nov 14. PMID: 29136387
  • Hussain M, Tangen CM, Thompson IM Jr, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 May 20;36(15):1498-1504. Epub 2018 Apr 6. PMID: 29624463
  • Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, Press OW. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Mar 1;36(7):697-703. Epub 2018 Jan 22. PMID: 29356608
  • Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. The Lancet. Oncology. 2018 Jan;19(1):101-114. Epub 2017 Nov 20. PMID: 29169877